BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 60 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $38,000 | -35.6% | 10,000 | -23.1% | 0.00% | -40.0% |
| Q4 2020 | $59,000 | -73.2% | 13,000 | 0.0% | 0.01% | -77.3% |
| Q3 2020 | $220,000 | +50.7% | 13,000 | 0.0% | 0.02% | +10.0% |
| Q2 2020 | $146,000 | +143.3% | 13,000 | 0.0% | 0.02% | +122.2% |
| Q1 2020 | $60,000 | +7.1% | 13,000 | 0.0% | 0.01% | +28.6% |
| Q4 2019 | $56,000 | +9.8% | 13,000 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $51,000 | -25.0% | 13,000 | -24.9% | 0.01% | -30.0% |
| Q2 2019 | $68,000 | -9.3% | 17,300 | 0.0% | 0.01% | -16.7% |
| Q1 2019 | $75,000 | +63.0% | 17,300 | +33.1% | 0.01% | +33.3% |
| Q4 2018 | $46,000 | +9.5% | 13,000 | +18.2% | 0.01% | 0.0% |
| Q3 2018 | $42,000 | -2.3% | 11,000 | 0.0% | 0.01% | -18.2% |
| Q2 2018 | $43,000 | +48.3% | 11,000 | +22.2% | 0.01% | +37.5% |
| Q1 2018 | $29,000 | -6.5% | 9,000 | 0.0% | 0.01% | 0.0% |
| Q4 2017 | $31,000 | – | 9,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |